Analysis of clinical characteristics and outcome of patients with very high risk primary immunoglobulin light-chain amyloidosis
10.3760/cma.j.issn.0253-2727.2017.02.005
- VernacularTitle: 极高危原发性轻链型淀粉样变患者的临床特征和预后分析
- Author:
Jun FENG
;
Xufei HUANG
;
Congli ZHANG
;
Kaini SHEN
;
Chunlan ZHANG
;
Jian SUN
;
Zhuang TIAN
;
Xinxin CAO
;
Lu ZHANG
;
Daobin ZHOU
;
Jian LI
1
Author Information
1. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China
- Publication Type:Journal Article
- Keywords:
Primary light chain amyloidosis;
Very high risk;
Bortezomib
- From:
Chinese Journal of Hematology
2017;38(2):107-111
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical characteristics and outcomes of very high risk patients with primary immunoglobulin light-chain amyloidosis (pAL) at a single center in China.
Method:Clinical data, treatment and outcome of 205 pAL patients in Peking Union Medical College Hospital from January 2009 to February 2016 were retrospectively analyzed. A 'very high risk’ group includes patients with Mayo 2004 stage Ⅲb and Mayo 2012 stage 4.
Results:Of 205 patients, 34 (16.6%) were defined as very high risk pAL patients. The median age at diagnosis was 57 (20-84) years, and 22 patients (64.7%) were male. All 34 patients were diagnosed with cardiac involvement, multi-organ involvement was observed in 15 patients (44.1%) , and 27 (81.8%) had New York Heart Association Class Ⅲ or Ⅳ. Median values of serum cTnI, NT-proBNP, and free light chains difference were 0.25 μg/L, 11 733 ng/L, and 403 mg/L, respectively. Eight (24.2%) had more than 10% plasma cell on the bone marrow aspirate. Sixteen (47.1%) patients received bortezomib based chemotherapy and overall hematologic response rate was 58.3%. Median overall survival (OS) was 4 months. The estimated OS at 3, 6, 12, and 24 months was 51.3%, 44.0%, 35.2%, and 29.6%, respectively. Fourteen (41.2%) patients died within 3 months after the diagnosis. The estimated 1-year survival rate for the patients who got hematologic response, without hematologic response, and palliative treatment was 90.9%, 11.1%, and 0, respectively (P<0.001) .
Conclusion:Patients with very high risk pAL had very poor prognosis and the early death rate remained high. Those patients who obtained hematologic remission would have significantly better outcomes.
